Evidence map›Paper›PMID 33807516›Full record

ReviewVaccines2021

VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases.

Aline Maria Vasconcelos Queiroz, Johny Wysllas de Freitas Oliveira, Cláudia Jassica Moreno, Diego M A Guérin, Marcelo Sousa Silva

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Long-TermJournal of immunology research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Aline Maria Vasconcelos QueirozImmunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.ORCID 0000-0002-1811-7376
Johny Wysllas de Freitas OliveiraImmunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.ORCID 0000-0002-3100-0420
Cláudia Jassica MorenoImmunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.ORCID 0000-0002-6948-9823
Diego M A GuérinInstituto Biofisika (CSIC-UPV/EHU), Department of Biochemistry and Molecular Biology, University of the Basque Country, 48940 Bizkaia, Spain.ORCID 0000-0001-8504-9636
Marcelo Sousa SilvaImmunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.ORCID 0000-0002-1000-0149
Universidade Federal do Rio Grande do Norte · BRUniversity of Lisbon · PTUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by

Indexed as

African trypanosomiasisChagas diseaseleishmaniasistrypanosomatidsvaccinevirus-like particles

Identifiers

PMID33807516
PMCPMC7998750
OpenAlexW3135623686

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.